Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.
Chekerov R, Harter P, Fuxius S, Hanker LC, Woelber L, Müller L, Klare P, Abenhardt W, Nedkova Y, Yalcinkaya I, Heinrich G, Sommer H, Mahner S, Wimberger P, Koensgen-Mustea D, Richter R, Oskay-Oezcelik G, Sehouli J; Ovarian Cancer Study Group of the North-Eastern German Society of Gynaecological Oncology (NOGGO). Chekerov R, et al. Among authors: mahner s. Gynecol Oncol Res Pract. 2017 Mar 7;4:6. doi: 10.1186/s40661-017-0040-2. eCollection 2017. Gynecol Oncol Res Pract. 2017. PMID: 28286660 Free PMC article.
Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G; North-Eastern German Society of Gynecological Oncology. Sehouli J, et al. Among authors: mahner s. Cancer Chemother Pharmacol. 2009 Aug;64(3):585-91. doi: 10.1007/s00280-008-0909-1. Epub 2009 Jan 21. Cancer Chemother Pharmacol. 2009. PMID: 19156414
Role of cytoreductive surgery in recurrent ovarian cancer.
Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, du Bois A. Harter P, et al. Among authors: mahner s. Expert Rev Anticancer Ther. 2009 Jul;9(7):917-22. doi: 10.1586/era.09.49. Expert Rev Anticancer Ther. 2009. PMID: 19589031 Review.
Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.
Woelber L, Mueller V, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Mahner S. Woelber L, et al. Among authors: mahner s. Gynecol Oncol. 2010 May;117(2):183-8. doi: 10.1016/j.ygyno.2009.11.029. Epub 2010 Jan 6. Gynecol Oncol. 2010. PMID: 20051287
A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.
Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W, Runnebaum I, Look K, Jaenicke F, Oskay-Oezcelik G. Sehouli J, et al. Among authors: mahner s. Cancer Chemother Pharmacol. 2010 Oct;66(5):861-8. doi: 10.1007/s00280-009-1230-3. Epub 2010 Jan 7. Cancer Chemother Pharmacol. 2010. PMID: 20054549 Clinical Trial.
484 results